Blog
RSS FeedPosted by Michael Wonder on 28 Apr 2022
Insights from the March 2022 PBAC meeting (part 3)
29 April 2022 - Wegovy was the first discrete medicine to have a stakeholder meeting before its consideration by the ...
Posted by Michael Wonder on 27 Apr 2022
Insights from the March 2022 PBAC meeting (part 2)
28 April 2022 The rejection of dostarlimab should not come as a surprise, the rejection of sotorsaib less so. ...
Posted by Michael Wonder on 26 Apr 2022
Insights from the March 2022 PBAC meeting (part 1)
26 April 2022 - Yesterday, we noted a recommendation rate of 78% which the highest value we have recorded since ...
Posted by Michael Wonder on 23 Apr 2022
Recommendations made by the PBAC - March 2022
22 April 2022 - The recommendations from the March 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 28 Feb 2022
New treatment for Australians with rare blood disease
28 February 2022 - Australians with paroxysmal nocturnal haemoglobinuria—a condition that produces defective blood cells—will have access to a new treatment ...
Posted by Michael Wonder on 25 Feb 2022
PBAC recommendation for molnupiravir (Lagevrio)
25 February 2022 - The PBAC undertook an expedited consideration of a sponsor submission (MSD) to add molnupiravir (Lagevrio) to the ...
Posted by Michael Wonder on 01 Feb 2022
'Lifesaving' cystic fibrosis drug Trikafta recommended for inclusion on PBS
1 February 2022 - Thousands of people with cystic fibrosis are one step closer to accessing a 'lifesaving' drug, after ...
Posted by Michael Wonder on 28 Jan 2022
Recommendations made by the PBAC – December 2021 intracycle meeting
28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 17 Dec 2021
Medicine agency recommends listing of life-saving drugs for Australian men with deadly forms of prostate cancer
17 December 2021 - Prostate Cancer Foundation of Australia has welcomed recommendations by Australia’s Pharmaceutical Benefits Advisory Committee to list ...
Posted by Michael Wonder on 17 Dec 2021
Recommendations made by the PBAC - November 2021
17 December 2021 - The recommendations from the November 2021 PBAC meeting are now available. ...
Posted by Michael Wonder on 05 Nov 2021
Drug Utilisation Sub-Committee outcome statement
5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...
Posted by Michael Wonder on 28 Oct 2021
Mallinckrodt and Terumo Blood and Cell Technologies announce positive recommendations in Australia for public funding of Uvadex (methoxsalen) for ECP administration with the Therakos Cellex photopheresis system for chronic graft versus host disease in adults
28 October 2021 - In a dual review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement ...
Posted by Michael Wonder on 17 Oct 2021
Recommendations made by the PBAC – September 2021 intracycle meeting
15 October 2021 - First PBAC recommendation for a new gene therapy. ...
Posted by Michael Wonder on 15 Oct 2021
Recommendations made between March 2021 and November 2021 PBAC meetings
15 October 2021 - Recommendations made by the PBAC between the March 2021 and November 2021 have been published. ...